Capricor Therapeutics Presents Phase 3 HOPE-3 Trial Results for Deramiocel in Duchenne Muscular Dystrophy at AAN 2026

Key Takeaways

• Capricor presented Phase 3 HOPE-3 trial data for Deramiocel in Duchenne muscular dystrophy at the American Academy of Neurology 2026 Annual Meeting
• The late-breaking presentation suggests potentially significant results for this novel cell and exosome-based therapeutic approach
• Deramiocel represents a differentiated mechanism of action compared to existing approved DMD treatments like eteplirsen and ataluren

---

SAN DIEGO - Capricor Therapeutics (NASDAQ: CAPR) announced April 22, 2026, that Phase 3 HOPE-3 clinical trial data for Deramiocel in Duchenne muscular dystrophy (DMD) was presented at the American Academy of Neurology (AAN) 2026 Annual Meeting in Chicago.

The presentation was delivered by Dr. Aravindhan Veerapandiyan, Associate Professor and Director at an undisclosed institution, marking a significant milestone for Capricor’s lead cell and exosome-based therapeutic program.

Novel Approach to DMD Treatment

Deramiocel represents a differentiated approach to treating DMD, utilizing cell and exosome-based mechanisms rather than the gene therapy or antisense oligonucleotide approaches employed by currently approved treatments. This novel mechanism could potentially address limitations seen with existing therapies.

Duchenne muscular dystrophy affects approximately 1 in 3,500 to 5,000 male births worldwide, causing progressive muscle degeneration and weakness. Current approved treatments include Sarepta Therapeutics’ eteplirsen and golodirsen, PTC Therapeutics’ ataluren, and Pfizer’s gene therapy fordadistrogene movaparvovec.

Market Context and Competition

The DMD therapeutic market has seen significant activity in recent years, with multiple companies developing treatments targeting different aspects of the disease. Capricor’s cell-based approach could potentially complement existing therapies or offer advantages in specific patient populations.

The late-breaking nature of the AAN presentation suggests the HOPE-3 results may contain noteworthy findings, as such slots are typically reserved for studies with significant clinical implications. However, specific efficacy and safety data from the presentation have not been disclosed in the announcement.

Regulatory Pathway Considerations

As a rare disease therapy, Deramiocel may be eligible for accelerated regulatory pathways, including FDA Fast Track designation, Breakthrough Therapy designation, or Priority Review. These designations could potentially expedite the path to market if Phase 3 results demonstrate meaningful clinical benefit.

Cell-based therapies face unique manufacturing and delivery challenges compared to traditional small molecule drugs, which regulatory agencies consider during the approval process. Capricor’s experience in developing cell and exosome-based therapeutics may provide advantages in navigating these complexities.

Investment and Development Implications

The presentation of Phase 3 data represents a critical inflection point for Capricor Therapeutics, as positive results could validate the company’s cell-based therapeutic platform and potentially attract partnership interest from larger pharmaceutical companies.

For patients and families affected by DMD, additional treatment options remain critically important given the progressive nature of the disease and varying patient responses to existing therapies. The potential for combination approaches or treatments targeting different disease mechanisms continues to drive research interest in this area.

Looking Forward

Capricor has not yet announced detailed results from the HOPE-3 trial or provided timelines for potential regulatory submissions. Investors and the DMD community will likely await more comprehensive data disclosure and guidance on next steps for the Deramiocel development program.

---

Frequently Asked Questions

What makes Deramiocel different from existing DMD treatments?

Deramiocel uses a cell and exosome-based mechanism of action, which differs from approved treatments like gene therapies (Pfizer’s fordadistrogene movaparvovec) and antisense oligonucleotides (Sarepta’s eteplirsen, golodirsen). This novel approach could potentially address different aspects of DMD pathology.

When will Deramiocel be available for patients?

Capricor has not provided specific timelines for regulatory submission or potential approval. The availability will depend on the Phase 3 HOPE-3 results and subsequent FDA review process, which could be expedited through rare disease regulatory pathways.

How significant is presenting at the American Academy of Neurology meeting?

The AAN Annual Meeting is a major neurology conference, and late-breaking presentations are typically reserved for studies with significant clinical implications. This suggests the HOPE-3 results may contain noteworthy findings, though specific data has not been disclosed.